AllSci News
Galecto makes secondary offering for USD 27.5m
Denmark-based Galecto, Inc. (Nasdaq: GLTO) announced the pricing of an underwritten public offering with total gross proceeds of USD 27.5 million. The…
Moderna receives Refusal-to-File letter from FDA for mRNA flu vaccine mRNA-1010
Moderna gave notice that the US FDA’s Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter for its investigational seasonal…
Leqembi subcutaneous formulation secures Priority Review for Alzheimer’s in China
Eisai and Biogen received a priority review award from China’s National Medical Products Administration (NMPA) for the subcutaneous formulation of Leqembi (lecanemab).…
Akeso moves first-in-class IL-4Rα/ST2 BsAb into Phase II for respiratory, autoimmune diseases
China-based Akeso Inc., (9926.HK) announced clearance from China’s National Medical Products Administration (NMPA) to initiate seven Phase II studies for its first-in-class…
Upstream Bio’s long-acting TSLP antibody set for Phase III after positive severe asthma trial
Upstream Bio announced positive top-line results from its Phase II VALIANT clinical trial evaluating verekitug asthma treatment, demonstrating statistically significant reductions in…
Pertussis vaccines firm ILiAD raises USD 115m in Series B
Weston, Florida-based ILiAD Biotechnologies, a clinical-stage biotechnology company focused on the prevention and treatment of diseases caused by Bordetella pertussis, has entered…
ProMIS Neurosciences raises USD 175m in private placement financing
ProMIS Neurosciences (Nasdaq: PMN) announced a private placement in public equity (PIPE) financing of up to approximately USD 175 million before fees…
Moderna finds partners in Mexico to boost mRNA vaccine supply
Moderna Inc., (NASDAQ: MRNA) signed a Memorandum of Understanding (MoU) for a five-year strategic agreement with the Government of Mexico, state-owned Laboratorios…
Roche’s fenebrutinib on par with Ocrevus for multiple sclerosis
Switzerland-based Roche announced positive late-breaking Phase III results from the FENtrepid study evaluating fenebrutinib in patients with primary progressive multiple sclerosis (PPMS).…
Galux secures USD 29m Series B to advance AI-driven protein therapeutics platform
South Korea-based biotechnology firm Galux, which focuses on de novo protein design for drug discovery, has completed a Series B financing round…
MerryLife Biomedical’s TML-6 shows promise in Phase I Alzheimer’s trial
Taiwan-based MerryLife Biomedical announced positive Phase I results for TML-6, an innovative oral Alzheimer’s therapy designed to target multiple neurological pathways simultaneously.…
Kailera, Hengrui to advance oral GLP-1/GIP drug ribupatide after showing 12.1% weight loss
Kailera Therapeutics and China-based Hengrui Pharma announced positive topline data from a Phase II trial for ribupatide in obesity, demonstrating significant weight…
Regenxbio’s Hunter syndrome drug met with FDA CRL
Regenxbio Inc., a Maryland-based biotechnology company, announced that the US FDA has issued a Complete Response Letter (CRL) regarding the Biologics License…
Adlai Nortye backed with USD 140m in strategic financing
Adlai Nortye Ltd. (Nasdaq: ANL), a clinical-stage biotech developing next-generation cancer immunotherapies and RAS-targeting therapies, entered into securities purchase agreements for a…
Lilly aims for in vivo autoimmune therapeutics via USD 2.4b acquisition of Orna Therapeutics
Eli Lilly and Co. has unveiled plans to acquire Orna Therapeutics, a Cambridge-based biotech specializing in in vivo engineered cell therapies. The…
The AllSci Brief
Systematic R&D and deal news. Daily.